NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293]

Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or
	appeal)
Company	<u>General</u>
Astra Zeneca (sodium zirconium	 Allied Health Professionals
cyclosilicate)	 All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Association of Renal Industries
Kidney Care UK	Board of Community Health Councils in
Kidney Research UK	Wales
Muslim Council of Great Britain	British National Formulary
National Kidney Federation	Care Quality Commission
 Pumping Marvellous Foundation 	Department of Health, Social Services
 South Asian Health Foundation 	and Public Safety for Northern Ireland
Specialised Healthcare Alliance	Healthcare Improvement Scotland
	Medicines and Healthcare Products
Professional groups	Regulatory Agency
 Association of Renal Technologists 	 National Association of Primary Care
British Geriatrics Society	 National Pharmacy Association
British Renal Society	NHS Alliance
Renal Association	NHS Confederation
Royal College of General Practitioners	Scottish Medicines Consortium
Royal College of Nursing	Welsh Health Specialised Services
Royal College of Pathologists	Committee
Royal College of Physicians	Welsh Kidney Patients Association
Royal Pharmaceutical Society	
Royal Society of Medicine	Comparator companies
UK Clinical Pharmacy Association	None
UK Renal Pharmacy Group	Polovant research groups
QU ₂ and	Relevant research groups
<u>Others</u>	Cochrane Kidney and Transplant MPC Clinical Trials Unit
Department of Health NUO Provident Oil 2000	MRC Clinical Trials Unit Netional Institute for Health Beaucreh
NHS Bradford City CCG NHS Bradford City CCG	National Institute for Health Research
NHS Bolton CCG	Associated Public Health Groups
NHS England	Public Health England
Welsh Government	Public Health Wales
	I UDIIC HEAIUI WAICS

Final matrix for the technology appraisal of sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293].

Issue date: May 2018.

© National Institute for Health and Care Excellence 2018. All rights reserved.

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Final matrix for the technology appraisal of sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293].

Issue date: May 2018.

© National Institute for Health and Care Excellence 2018. All rights reserved.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

Final matrix for the technology appraisal of sodium zirconium cyclosilicate for treating hyperkalaemia [ID1293].

Issue date: May 2018.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.

[©] National Institute for Health and Care Excellence 2018. All rights reserved.